TABLE 4.

Toxoplasma DNA detection in allo-HSCT patients according to PCR follow-up policy^a

Characteristic	Result for centers with:		P valuec
	PCR follow-up (6 centers)	No PCR follow-up (5 centers)
Annual no. of allografts	410	330
Annual no. of PCRs (mean ± SEM)	796 ± 624	48 ± 26	0.0095**
No. of PCRs/no. of allo-HSCT patients (mean ± SEM)	10 ± 2.8	0.6 ± 0.2	0.0043**
No. of patients with PCR+ test	56	16	NA
No. of PCR+ patients/no. engrafted (%, mean ± SEM)	4.9 ± 1.6	1.7 ± 0.6	0.177 (NS)
Asymptomatic patients with PCR+ test
Total no. of patients	23	0	0.0015**
No. detected/no. engrafted (%, mean ± SEM)	2.1 ± 0.8	NA
Type of positive sample	Blood	NA
No. of PCR+ results/patient (mean ± SEM)	1.7 ± 0.6	NA
No. of patients under chemoprophylaxis	8	NA
No. (%) treated	17b (74)	NA
No. (%) that survived	23 (100)	NA
Symptomatic PCR+ patients
Total no. PCR+ patients	33	16
No. detected/no. engrafted (%, mean ± SEM)	2.8 ± 0.9	1.7 ± 0.6	0.329 (NS)
No. (%) with:
Disseminated toxoplasmosis	21 (64)	9 (56)	0.756 (NS)
Cerebral toxoplasmosis	8 (24)	4 (25)	1 (NS)
Isolated fever	3 (9)	2 (13)	0.672 (NS)
Ocular toxoplasmosis	1 (3)	1 (6)	1 (NS)
No. (%) that survived	25 (76)	8 (50)	0.106 (NS)
Overall survival (%) of the 72 patients	48 (86)	8 (50)	0.005**

^aIn total, this analysis included data for 72 patients from 11 centers whose policies did or did not include PCR follow-up. NA, not applicable.

^bThe six untreated patients received chemoprophylaxis.

^c**, P < 0.01; NS, not significant.